[Reversible posterior leukoencephalopathy induced by tacrolimus in a renal transplant patient].
Izquierdo Pajuelo
M J
MJ
Jiménez Delgado
J D
JD
Rangel Mayoral
J F
JF
Liso Rubio
F J
FJ
D001766:Blindness / Q000139:chemically induced / Q000473:pathology; D003128:Coma / Q000139:chemically induced / Q000473:pathology; D004359:Drug Therapy, Combination; D004830:Epilepsy, Tonic-Clonic / Q000139:chemically induced; D005260:Female; D006084:Graft Rejection / Q000188:drug therapy / Q000628:therapy; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage / Q000009:adverse effects*; D016030:Kidney Transplantation; D008279:Magnetic Resonance Imaging; D008775:Methylprednisolone / Q000627:therapeutic use; D009173:Mycophenolic Acid / Q000008:administration & dosage / Q000031:analogs & derivatives / Q000627:therapeutic use; D009778:Occipital Lobe / Q000473:pathology; D054038:Posterior Leukoencephalopathy Syndrome / Q000139:chemically induced* / Q000473:pathology; D011183:Postoperative Complications / Q000139:chemically induced*; D006435:Renal Dialysis; D016559:Tacrolimus / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D055815:Young Adult
D007166:Immunosuppressive Agents; D009173:Mycophenolic Acid; D016559:Tacrolimus; D008775:Methylprednisolone